GlassScriptPhysician profile
Daniel F Arnoldi
NPI 1184726291
$3,069.84
in general payments reported to CMS, 2019-2025
23 companies · $489 in 2025
The $489 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $201 · 2021: $206 · 2022: $180 · 2023: $957 · 2024: $651 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $837.22 | 2019-2024 | Omni Surgical System, Tearcare System |
| Heru, INC. | $452.20 | 2023 | Heru Hmd |
| Alcon Vision LLC | $319.80 | 2023-2025 | Clareon, Rocklatan, Argos |
| Novartis Pharmaceuticals Corporation | $248.15 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $189.67 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $151.49 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $144.44 | 2022-2023 | Vyzulta, Lotemax Sm, Prolensa |
| Tarsus Pharmaceuticals, INC. | $113.18 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $100.69 | 2022-2024 | Tyrvaya |
| Rxsight INC | $93.75 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ivantis, INC | $71.43 | 2020 | |
| Allergan, INC. | $57.50 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.71 | 2019-2021 | |
| Thea Pharma INC. | $36.29 | 2024-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $32.72 | 2024-2025 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $30.55 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $29.15 | 2020-2021 | |
| Dompe US, INC. | $29.04 | 2022-2024 | Oxervate |
| Ani Pharmaceuticals, INC. | $24.90 | 2024 | Purified Cortrophin Gel |
| Maculogix, INC. | $20.25 | 2019 | |
| Amgen INC. | $16.65 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $15.52 | 2021 | |
| Shire North American Group INC | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arnoldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.